Markers of brain cell development may help success of stem cell transplantsSeptember 07, 2005Story by Toni Baker Four sugar-coated faces made by stem cells as they differentiate into brain cells during development have been identified by scientists. These unique expressions of sugar on the cell surface may one day enable stem cell therapy to repair brain injury or disease by helping stem cells navigate the relative "jungle" of the adult brain, says Dr. Robert K. Yu, director of the Institute of Neuroscience and the Institute for Molecular Medicine and Genetics at the Medical College of Georgia. "These glycoconjugate markers are like specific addresses that characterize the cell at that particular moment. We call them stage-specific embryonic antigens," says Dr. Yu of recognition molecules that assist in the unbelievably rapid assemblage of 100 billion to 200 billion cells into a brain in nine months. The four compounds - two glycolipids, GD3 and O-acetylated GD3, and two glycoproteins, Stage-specific Embryonic Antigen-1 and Human Natural Killer Cell Antigen 1 - were known, but their role in helping cells migrate where and when needed was unknown. The findings of Dr. Yu, Postdoctoral Fellow Makoto Yanagisawa and Dr. Sean Liour, co-director of MCG's Human Stem Cell Bank, are being presented during the biannual International Symposium on Glycoconjugates, Sept. 4-9 in Florence, Italy. Dr. Yu is a meeting organizer and is chairing the session on Regulatory Mechanisms for Glycolipid Expression and Intracellular Trafficking. "We are all sugar-coated, really," says Dr. Yu, who studies these cell surface molecules that change constantly during development. "There is an abundance of sugar on the cell surface, not only that defines the cell's properties but also help cells recognize each other and stick together," he says, noting how like cells bind to form an organ. During brain formation, for example, cells are constantly changing their sugar face and their function to meet the immediate biological needs. They travel a sort of neuron interstate laid out by the first stem cells formed in development before rapid cell migration and transformation begins. "These 'interstates' are called Bergmann glia or glial fibers. They serve as guidance for the neuronal cells to migrate," Dr. Yu says of the network that is maintained in the adult brain despite the fact that mature neurons don't really change. Conditions such as trauma, spinal cord injury and stroke can destroy these travel networks as well as brain cells. Labs such as Dr. Yu's are doing stem cell transplants to re-establish roadways and get undifferentiated stem cells to repopulate such ravaged areas. He hopes the new developmental markers will help in this effort by showing what cell surface molecules should look like - and consequently how the cells should act - at certain points along the way. Two of the biggest problems facing stem cell transplantation are functional recovery - getting the cells to do the right job once they arrive at a target organ - and controlling their proliferation so they don't start forming tumors, says Dr. Yu. MCG Biochemist Erhard Bieberich is exploring the potential of the lipid ceramide, which helps eliminate potentially harmful cells during brain development, to halt unwanted proliferation of transplanted stem cells. Dr. Yu hopes the new developmental markers will help with the other problem. "There are other players, but these are important factors that help the brain form. I think it's a good start. Now that we have these to use as examples, discovery of other markers should come faster." The work was funded by the National Institutes of Health, the Children's Medical Research Foundation in Chicago and the Cerebral Ataxia Association in Taiwan. Medical College of Georgia |
|||||||||||||||||||||
| Related Stem Cell Transplant Current Events and Stem Cell Transplant News Articles Your Own Stem Cells Can Treat Heart Disease The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells. First use of antibody and stem cell transplantation to successfully treat advanced leukemia For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. Immunotherapy demonstrates long-term success in treating lymphoma Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT). Private umbilical cord banking not cost-effective, UCSF research shows Private cord blood banking is not cost-effective because it costs an additional $1,374,246 per life-year gained, according to a new analysis by UCSF researchers. Rare genetic disease successfully reversed using stem cell transplantation A recent study by Scripps Research Institute scientists offers good news for families of children afflicted with the rare genetic disorder, cystinosis. Immunotherapy effective against neuroblastoma in children A phase III study has shown that adding an antibody-based therapy that harnesses the body's immune system resulted in a 20 percent increase in the number of children living disease-free for at least two years with neuroblastoma. UBC research finds molecular University of British Columbia researchers have discovered a "molecular key" that could help increase the success of blood stem cell transplants, a procedure currently used to treat diseases such as leukemia, Hodgkin's lymphoma and aplastic anemia. World premiere in stem cell research in Montreal A team from the Institute for Research in Immunology and Cancer (IRIC) at Université de Montréal has succeeded in producing a large quantity of laboratory stem cells from a small number of blood stem cells obtained from bone marrow. Adult stem cell injections may reduce pain and improve walking in severe angina patients Preliminary data presented on March 28 as a late-breaking abstract at the American College of Cardiology's 58th annual scientific session from the largest CD34+ adult stem cell study for heart disease has shown the first evidence that delivering a potent form of autologous (from the patient) adult stem cells into the heart muscle of patients with severe angina may result in less pain and improved exercise tolerance. Survey: Few physicians support private banking of umbilical cord blood A survey of physicians has found broad support for the position that parents should not bank their newborns' umbilical cord blood in a private blood bank unless another member of the family is at risk for a blood disease that will require a stem cell transplant. More Stem Cell Transplant Current Events and Stem Cell Transplant News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||